Charles Schwab’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.47M | Sell |
190,077
-4,552
| -2% | -$59.2K | ﹤0.01% | 2603 |
|
|
2025
Q1 | $2.06M | Sell |
194,629
-13,173
| -6% | -$140K | ﹤0.01% | 2611 |
|
|
2024
Q4 | $3.53M | Buy |
207,802
+10,180
| +5% | +$173K | ﹤0.01% | 2498 |
|
|
2024
Q3 | $4.59M | Buy |
197,622
+3,224
| +2% | +$74.8K | ﹤0.01% | 2418 |
|
|
2024
Q2 | $4.73M | Buy |
194,398
+3,632
| +2% | +$88.4K | ﹤0.01% | 2382 |
|
|
2024
Q1 | $6.44M | Buy |
190,766
+4,456
| +2% | +$150K | ﹤0.01% | 2192 |
|
|
2023
Q4 | $5.87M | Buy |
186,310
+2,369
| +1% | +$74.7K | ﹤0.01% | 2235 |
|
|
2023
Q3 | $4.7M | Buy |
183,941
+5,435
| +3% | +$139K | ﹤0.01% | 2289 |
|
|
2023
Q2 | $5.12M | Sell |
178,506
-870
| -0.5% | -$25K | ﹤0.01% | 2229 |
|
|
2023
Q1 | $4.3M | Buy |
179,376
+825
| +0.5% | +$19.8K | ﹤0.01% | 2277 |
|
|
2022
Q4 | $3.03M | Buy |
178,551
+7,727
| +5% | +$131K | ﹤0.01% | 2433 |
|
|
2022
Q3 | $2.53M | Buy |
170,824
+14,566
| +9% | +$216K | ﹤0.01% | 2517 |
|
|
2022
Q2 | $2.46M | Buy |
156,258
+1,707
| +1% | +$26.9K | ﹤0.01% | 2499 |
|
|
2022
Q1 | $4.17M | Buy |
154,551
+3,704
| +2% | +$99.9K | ﹤0.01% | 2361 |
|
|
2021
Q4 | $5.58M | Buy |
150,847
+1,287
| +0.9% | +$47.6K | ﹤0.01% | 2297 |
|
|
2021
Q3 | $7.15M | Buy |
149,560
+4,939
| +3% | +$236K | ﹤0.01% | 2203 |
|
|
2021
Q2 | $4.89M | Buy |
144,621
+6,095
| +4% | +$206K | ﹤0.01% | 2366 |
|
|
2021
Q1 | $5.72M | Buy |
138,526
+2,696
| +2% | +$111K | ﹤0.01% | 2231 |
|
|
2020
Q4 | $5.89M | Buy |
135,830
+18,788
| +16% | +$815K | ﹤0.01% | 2139 |
|
|
2020
Q3 | $5.02M | Buy |
117,042
+83,449
| +248% | +$3.58M | ﹤0.01% | 2054 |
|
|
2020
Q2 | $1.57M | Buy |
+33,593
| New | +$1.57M | ﹤0.01% | 2498 |
|